A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/395 (2006.01) A61P 7/02 (2006.01) A61P 9/10 (2006.01) A61P 35/04 (2006.01) C07K 16/28 (2006.01)
Patent
CA 2428649
The invention relates to the use of special antibodies optimised by phage- display of optimised antibodies against GPIIb/IIIa for combined inhibition of fibrinogen to platelets and the vitronectin binding to endothelial cells for therapy and/or prophylaxis of vascular clusion. The invention also relates to the use of said antibodies for inhibiting angiogenesis or/and for inhibiting the metastasis of tumours or/and for inhibiting intimal hyperplasia following vascular damage.
L'invention concerne l'utilisation d'anticorps spéciaux, optimisés par expression phagique, agissant contre la GPIIb/IIIa pour l'inhibition combinée de la liaison fibrinogène sur des plaquettes et de la liaison vitronectine sur des cellules endothéliales, dans le cadre de la thérapie et/ou de la prophylaxie de l'occlusion vasculaire. La présente invention porte également sur l'utilisation de ces anticorps pour inhiber l'angiogenèse et/ou la formation de métastases tumorales et/ou l'hyperplasie de l'intima à la suite d'endommagements vasculaires.
Berchtold Peter
Escher Robert
Asat Ag Applied Science & Technology
Ogilvy Renault Llp/s.e.n.c.r.l.,s.r.l.
LandOfFree
Recombined anti-gpiib/iiia antibodies used for inhibiting... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombined anti-gpiib/iiia antibodies used for inhibiting..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombined anti-gpiib/iiia antibodies used for inhibiting... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1542060